Today reported promising early safety and response results from newly diagnosed acute myeloid leukemia (AML) patients dosed in Aptose’s Phase 1/2 TUSCANY trial with a 40 mg dose of tuspetinib in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback